Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
-
21
Flow chart of the study procedures.
Published 2023“…</p><p>Conclusions</p><p>In a mostly HIV patient population, RPR titer can show more than four-fold spontaneous increase or decrease within 1–3 months. …”
-
22
Fold change with steady state myocardial mRNA levels for components of the inflammasome.
Published 2024Subjects: -
23
-
24
5-fold cross-validation comparison results.
Published 2025“…The computational cost decreased from 11.6 GFlops to 6.6 GFlops.</p></div>…”
-
25
TUDCA decreases ER stress in HOX neonatal rat lungs.
Published 2022“…<p>(<b>A</b>) The expression levels of ER stress markers (P-PERK 0.6±0.1-fold, p<0.001, n = 5; PERK 0.7±0.1-fold, p = 0.00364, n = 5; P-IRE1α 0.6±0.0-fold, p<0.001, n = 5; IRE1α 0.6±0.1-fold, p<0.001, n = 5; GRP78 0.8±0.1-fold, p<0.001, n = 5; cleaved ATF6 0.1±0.0-fold, p<0.001, n = 5; spliced XBP1 0.3±0.0-fold, p<0.001, n = 5; 2 males and 3 females) are all decreased while the N-glycosylated VEGFR2 is increased (3.5±0.2-fold, p<0.001, n = 5) in HOX neonatal lungs at P10 indicating TUDCA can attenuate hyperoxia-induced ER stress. …”
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
Performance of selected antimalarials against field isolates during the study period.
Published 2024Subjects: -
35
-
36
-
37
Performance of selected drugs against field isolates during the study period.
Published 2024Subjects: -
38
<i>In vitro</i> susceptibility responses of field isolates to antimalarials during the study period.
Published 2024Subjects: -
39
-
40
Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period.
Published 2024Subjects: